On November 2, 2021, Cambridge Epigenetix, a life sciences tools and technology company revolutionizing genome sequencing, announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital, and Sequoia. Wilson Sonsini Goodrich & Rosati advised Cambridge Epigenetix on IP matters related to the transaction.

Proceeds from the financing will be used to commercialize the company’s proprietary genetic and epigenetic sequencing technology, which easily integrates into existing sequencing platforms to enable more information to be read from DNA. The technology has been validated by leading genomic research institutions of which several, including Professor Dennis Lo of The Chinese University of Hong Kong, and Professor Wolf Reik of the Babraham Institute, have continued using the technology through early access programs.

The Wilson Sonsini team that advised Cambridge Epigenetix on IP matters related to the transaction includes Vern Norviel, Srividya Chandramouli, and Adam Cole.

For more information, please see Cambridge Epigenetix’s press release.